{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:46:36Z","timestamp":1777419996755,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the pharmacology, microbiology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of dalbavancin, a new semisynthetic lipoglycopeptide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A MEDLINE search, restricted to the English language, was conducted from 1966 through January 2006. Supplementary sources included program abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society of Microbiology, and the Infectious Diseases Society of America from 2000 to 2005 and information available from the manufacturer's Web site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>In vitro and preclinical studies, as well as Phase I, II, and III clinical trials, were evaluated to summarize the microbiology, pharmacology, clinical efficacy, and safety of dalbavancin. All published trials and abstracts citing dalbavancin were selected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Dalbavancin, a novel lipoglycopeptide, has a mechanism of action similar to that of other glycopeptides. It has in vitro activity against a variety of gram-positive organisms, but no activity against gram-negative or vancomycin-resistant enterococci that possess VanA gene. Due to its prolonged half-life (6\u201310 days), dalbavancin can be administered intravenously once weekly. In Phase II and III clinical trials, dalbavancin was effective and well tolerated for the treatment of skin and soft-tissue infections, catheter-related bloodstream infections, and skin and skin-structure infections. To date, adverse events are mild and limited; the most common include pyrexia, headache, nausea, oral candidiasis, diarrhea, and constipation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dalbavancin appears to be a promising antimicrobial agent for the treatment of gram-positive infections. A new drug application was filed with the Food and Drug Administration (FDA) in December 2004. The FDA issued an approvable letter in 2005 for dalbavancin. If approved, dalbavancin is expected to be launched in the first quarter of 2006.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g158","type":"journal-article","created":{"date-parts":[[2006,2,28]],"date-time":"2006-02-28T21:48:20Z","timestamp":1141163300000},"page":"449-460","source":"Crossref","is-referenced-by-count":26,"title":["Dalbavancin: A New Option for the Treatment of Gram-Positive Infections"],"prefix":"10.1177","volume":"40","author":[{"given":"Shu-Wen","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, University of Michigan Health System"},{"name":"Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI"},{"name":"Infectious Diseases, Department of Pharmacy Services, Hahnemann University Hospital, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L","family":"Carver","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Michigan Health System"},{"name":"Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl D","family":"DePestel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Michigan Health System"},{"name":"Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,3,1]]},"reference":[{"key":"bibr1-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.004"},{"key":"bibr2-aph.1G158","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013371716"},{"key":"bibr3-aph.1G158","first-page":"229","volume":"3","author":"Steiert M","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"bibr4-aph.1G158","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464090-00001"},{"key":"bibr5-aph.1G158","unstructured":"Vicuron Pharmaceuticals. www.vicuron.com\/j7\/servlet\/HomePage (accessed 2005 Jun 16)."},{"key":"bibr6-aph.1G158","unstructured":"Pfizer, Inc. www.pfizer.com\/pfizer\/are\/investors_releases\/2005pr\/mn_2005_1020.jsp (accessed 2006 Jan 21)."},{"key":"bibr7-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.117"},{"key":"bibr8-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.3.379"},{"key":"bibr9-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2001.13.3.244"},{"key":"bibr10-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5413.507"},{"key":"bibr11-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1021\/cr030103a"},{"key":"bibr12-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.781"},{"key":"bibr13-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki005"},{"key":"bibr14-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.03.004"},{"key":"bibr15-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.179"},{"key":"bibr16-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.1061-1064.2004"},{"key":"bibr17-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1086\/379015"},{"key":"bibr18-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-004-1626-2"},{"key":"bibr19-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1968-1971.2003"},{"key":"bibr20-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(03)00120-0"},{"key":"bibr21-aph.1G158","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.56.773"},{"key":"bibr22-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5182-5184.2005"},{"key":"bibr23-aph.1G158","author":"Jones RN","year":"2003","journal-title":"Abstract of the 41st Annual Meeting of the Infectious Diseases Society of America"},{"key":"bibr24-aph.1G158","author":"Appelbaum PC","year":"2003","journal-title":"Abstracts of the 41st Annual Meeting of Infectious Diseases Society of America"},{"key":"bibr25-aph.1G158","author":"Flamm RK","year":"2004","journal-title":"Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr26-aph.1G158","author":"Jones RN","year":"2004","journal-title":"Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr27-aph.1G158","author":"Andes DR","year":"2004","journal-title":"Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr28-aph.1G158","author":"Hackbarth CJ","year":"1999","journal-title":"Abstracts of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr29-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.01051.x"},{"key":"bibr30-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.770-772.2005"},{"key":"bibr31-aph.1G158","volume-title":"Performance standards for antimicrobial susceptibility testing (M1000\u2013S13)","author":"Reference method for MIC testing.","year":"2003"},{"key":"bibr32-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.07.008"},{"key":"bibr33-aph.1G158","volume-title":"Reference method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7\u2013A6","year":"2003"},{"key":"bibr34-aph.1G158","author":"Morrissey I","year":"2005","journal-title":"Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr35-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki007"},{"key":"bibr36-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.940-945.2004"},{"key":"bibr37-aph.1G158","author":"Dowell JA","year":"2004","journal-title":"Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr38-aph.1G158","author":"White RJ","year":"2000","journal-title":"Abstracts of the 40th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"bibr39-aph.1G158","first-page":"291","volume":"9","author":"Dowell J","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"bibr40-aph.1G158","author":"Dowell JA","year":"2002","journal-title":"Abstracts of the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr41-aph.1G158","author":"Dowell JA","year":"2005","journal-title":"Abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"bibr42-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki006"},{"key":"bibr43-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005280378"},{"key":"bibr44-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1118-1123.2004"},{"key":"bibr45-aph.1G158","author":"Candiani GP","year":"2001","journal-title":"Abstracts of the 41st Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr46-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"bibr47-aph.1G158","author":"Goldstein BP","year":"2005","journal-title":"Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr48-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"bibr49-aph.1G158","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1715720"},{"key":"bibr50-aph.1G158","author":"Johnson D","year":"2005","journal-title":"Abstracts of the 105th General Meeting of the American Society of Microbiology"},{"key":"bibr51-aph.1G158","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464150-00002"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:12:05Z","timestamp":1777374725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1345\/aph.1G158"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g158","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}